Tarsier Pharma Ltd. has filed to raise capital through an initial public offering of its ordinary shares, each with a par value of NIS 0.001, the company said in a statement.
In regulatory filings, Tarsier indicated an expected offering price range of $8.00 to $10.00 per share. The filing notes that calculations in the document were prepared using an assumed midpoint price of $9.00 per share.
The company has applied to list its ordinary shares on the New York Stock Exchange under the ticker symbol NYSE: TARX. At present, there is no public market for the company’s shares.
Konik Capital Partners is named as the underwriter for the offering. The filing emphasizes that the proposed public offering and prospective listing are contingent on approval of the NYSE listing application - with no assurance that such approval will be granted or that a trading market for the shares will emerge.
Context and implications
The filing represents Tarsier Pharma’s formal step toward accessing public equity markets through a proposed stock offering. Beyond signaling the company’s intent to list in the United States and to engage public investors, the filing contains the procedural caveats typical of IPO registrations: a stated price range, an identified underwriter, and the requirement of exchange approval before shares can trade publicly.
Summary
- Tarsier Pharma filed for an IPO of ordinary shares with par value NIS 0.001.
- The company estimates an offering price between $8.00 and $10.00 per share and used a $9.00 midpoint for calculations.
- Tarsier has applied to list on the New York Stock Exchange under NYSE: TARX; there is presently no public market for its shares.
- Konik Capital Partners is the underwriter, and the offering depends on NYSE approval.
The information in this filing outlines the company’s near-term path to public markets but does not guarantee that a market for the shares will be established or that the NYSE will approve the listing application.